MAGLE Stock Overview
Operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Magle Chemoswed Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 34.20 |
| 52 Week High | SEK 49.80 |
| 52 Week Low | SEK 23.20 |
| Beta | 0.56 |
| 11 Month Change | 8.92% |
| 3 Month Change | -15.35% |
| 1 Year Change | 35.71% |
| 33 Year Change | 17.93% |
| 5 Year Change | n/a |
| Change since IPO | 66.75% |
Recent News & Updates
Recent updates
Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Weaker Than They Seem
Nov 04
Market Participants Recognise Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Earnings Pushing Shares 37% Higher
Jun 26Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet
Jun 19Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality
Apr 26Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%
Mar 29Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Price In Tune With Earnings
Oct 05Should You Be Impressed By Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) ROE?
Jan 22Shareholder Returns
| MAGLE | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | -7.1% | -0.4% | -2.1% |
| 1Y | 35.7% | 33.2% | 16.4% |
Return vs Industry: MAGLE exceeded the Swedish Life Sciences industry which returned 33.3% over the past year.
Return vs Market: MAGLE exceeded the Swedish Market which returned 14.2% over the past year.
Price Volatility
| MAGLE volatility | |
|---|---|
| MAGLE Average Weekly Movement | 7.4% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: MAGLE has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: MAGLE's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 147 | Justin Pierce | www.maglechemoswed.com |
Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; amantadine sulfate that is used in the treatment of central nervous system disorders; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company’s microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures.
Magle Chemoswed Holding AB (publ) Fundamentals Summary
| MAGLE fundamental statistics | |
|---|---|
| Market cap | SEK 629.35m |
| Earnings (TTM) | SEK 16.75m |
| Revenue (TTM) | SEK 209.21m |
37.6x
P/E Ratio3.0x
P/S RatioIs MAGLE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAGLE income statement (TTM) | |
|---|---|
| Revenue | SEK 209.21m |
| Cost of Revenue | SEK 25.74m |
| Gross Profit | SEK 183.48m |
| Other Expenses | SEK 166.73m |
| Earnings | SEK 16.75m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | 0.91 |
| Gross Margin | 87.70% |
| Net Profit Margin | 8.00% |
| Debt/Equity Ratio | 25.4% |
How did MAGLE perform over the long term?
See historical performance and comparison